AstraZeneca (AZN) Set to Announce Earnings on Thursday

AstraZeneca (NYSE:AZN) will be posting its quarterly earnings results before the market opens on Thursday, February 14th. Analysts expect AstraZeneca to post earnings of $0.76 per share for the quarter.

AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.38. The firm had revenue of $5.34 billion during the quarter, compared to analysts’ expectations of $5.26 billion. AstraZeneca had a net margin of 11.29% and a return on equity of 27.32%. AstraZeneca’s revenue for the quarter was down 14.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.12 EPS. On average, analysts expect AstraZeneca to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

AZN stock opened at $36.87 on Thursday. The company has a market capitalization of $93.11 billion, a price-to-earnings ratio of 8.61, a PEG ratio of 1.95 and a beta of 0.51. The company has a debt-to-equity ratio of 1.36, a current ratio of 0.86 and a quick ratio of 0.66. AstraZeneca has a one year low of $32.69 and a one year high of $41.78.

Several analysts have commented on the stock. Deutsche Bank reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Monday, November 12th. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Credit Suisse Group reiterated a “buy” rating on shares of AstraZeneca in a report on Sunday, December 9th. Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a report on Friday, November 16th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $42.00 price target on shares of AstraZeneca in a report on Tuesday, December 11th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. AstraZeneca currently has an average rating of “Hold” and a consensus price target of $45.50.

ILLEGAL ACTIVITY WARNING: This story was first reported by Modern Readers and is owned by of Modern Readers. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Federal Reserve

Earnings History for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply